For instance, simultaneous inhibition of the CCL2 and CCL5, which are necessary chemokines for attracting TAMs to the TME and upregulated on hepatocellular carcinoma tumor cells, by a bispecific nanobody (BisCCL2/5i) demonstrated more survival benefits than the combination of two full-length antibodies or two small molecules against CCL2 and CCL5 in vivo. Here, CCL5 is linked to hepatocellular carcinoma.